دورية أكاديمية
أعرض في EDS

Paclitaxel hyperthermia suppresses gastric cancer migration through MiR-183-5p/PPP2CA/AKT/GSK3β/β-catenin axis.

التفاصيل البيبلوغرافية
العنوان: Paclitaxel hyperthermia suppresses gastric cancer migration through MiR-183-5p/PPP2CA/AKT/GSK3β/β-catenin axis.
المؤلفون: Yang X; Department of Anus and Intestine Surgery, The First People's Hospital of Foshan, Foshan, 528000, China., Liu C; Medical Affair Department, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China., Li Z; Second Department of Gastrointestinal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China., Wen J; Department of Medical Oncology, Puning People's Hospital, Puning, 515300, China., He J; Second Department of Gastrointestinal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China., Lu Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China., Liao Q; First Department of General Surgery, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, 511518, China., Wang T; Second Department of Gastrointestinal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China., Tang H; Second Department of Gastrointestinal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China. 15913139343@163.com., Yang X; Department of Medical Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China. yangxz@gzhmu.edu.cn., Zeng L; Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China. zenglisi2017@163.com.
المصدر: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Sep 09; Vol. 150 (9), pp. 416. Date of Electronic Publication: 2024 Sep 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin ; New York : Springer-Verlag.
مواضيع طبية MeSH: Stomach Neoplasms*/pathology , Stomach Neoplasms*/genetics , Stomach Neoplasms*/metabolism , MicroRNAs*/genetics , Glycogen Synthase Kinase 3 beta*/metabolism , Glycogen Synthase Kinase 3 beta*/genetics , Cell Movement* , Hyperthermia, Induced*/methods , beta Catenin*/metabolism , beta Catenin*/genetics , Proto-Oncogene Proteins c-akt*/metabolism, Humans ; Mice ; Animals ; Male ; Female ; Protein Phosphatase 2/metabolism ; Protein Phosphatase 2/genetics ; Cell Line, Tumor ; Mice, Nude ; Xenograft Model Antitumor Assays ; Gene Expression Regulation, Neoplastic ; Prognosis ; Middle Aged ; Mice, Inbred BALB C ; Antineoplastic Agents, Phytogenic/pharmacology
مستخلص: Background: Gastric cancer (GC), a prevalent malignant tumor which is a leading cause of death from malignancy around the world. Peritoneal metastasis accounts for the major cause of mortality in patients with GC. Despite hyperthermia intraperitoneal chemotherapy (HIPEC) improves the therapeutic effect of GC, it's equivocal about the mechanism under HIPEC.
Methods: MiR-183-5p expression was sifted from miRNA chip and detected in both GC patients and cell lines by qRT-PCR. Gene interference and rescue experiments were performed to identified biological function in vitro and vivo. Next, we affirmed PPP2CA as targeted of miR-183-5p by dual luciferase reporter assay. Finally, the potential relationship between HIPEC and miR-183-5p was explored.
Results: MiR-183-5p is up-regulated in GC and associated with advanced stage and poor prognosis. MiR-183-5p accelerate GC migration in vitro which is influenced by miR-183-5p/PPP2CA/AKT/GSK3β/β-catenin Axis. HIPEC exerts migration inhibition via attenuating miR-183-5p expression.
Conclusion: MiR-183-5p can be used as a potential HIPEC biomarker in patients with CC.
(© 2024. The Author(s).)
References: Cell Mol Life Sci. 2011 Sep;68(18):3033-46. (PMID: 21637948)
Nat Struct Mol Biol. 2012 Jun 05;19(6):586-93. (PMID: 22664986)
Curr Biol. 2014 Aug 18;24(16):R762-76. (PMID: 25137592)
Cancer Manag Res. 2019 Nov 14;11:9675-9683. (PMID: 31814763)
Br J Cancer. 2014 Apr 15;110(8):2000-10. (PMID: 24642616)
Nat Rev Genet. 2009 Oct;10(10):704-14. (PMID: 19763153)
J Clin Med. 2022 Mar 07;11(5):. (PMID: 35268546)
Nat Rev Genet. 2004 Sep;5(9):691-701. (PMID: 15372092)
J Biol Chem. 2007 Sep 14;282(37):26971-26980. (PMID: 17635907)
Cancer Res. 2003 May 1;63(9):2172-8. (PMID: 12727836)
Cell Death Differ. 2021 Sep;28(9):2708-2727. (PMID: 33875796)
Protein Cell. 2017 Feb;8(2):114-122. (PMID: 27844448)
Mol Cancer. 2020 Mar 19;19(1):62. (PMID: 32192494)
Clin Transl Oncol. 2023 Apr;25(4):1011-1016. (PMID: 36401054)
J Exp Med. 2019 May 6;216(5):1016-1026. (PMID: 30975895)
Trends Cell Biol. 2019 Mar;29(3):212-226. (PMID: 30594349)
Tumour Biol. 2014 Dec;35(12):12189-200. (PMID: 25179839)
RNA. 2019 Jan;25(1):1-16. (PMID: 30333195)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Dig Dis Sci. 2020 Feb;65(2):457-463. (PMID: 31441000)
J Surg Oncol. 2022 Jun;125(7):1176-1182. (PMID: 35481913)
Cell Death Dis. 2020 Apr 16;11(4):233. (PMID: 32300102)
Cell Physiol Biochem. 2015;35(3):933-44. (PMID: 25633747)
Hum Reprod Update. 2019 Jan 1;25(1):114-133. (PMID: 30407544)
Int J Mol Med. 2018 Dec;42(6):3562-3570. (PMID: 30221685)
EMBO J. 2000 Nov 1;19(21):5682-91. (PMID: 11060019)
Int J Clin Exp Pathol. 2014 Aug 15;7(9):5582-94. (PMID: 25337200)
Oncol Rep. 2019 Dec;42(6):2371-2381. (PMID: 31638242)
Pathol Res Pract. 2019 Nov;215(11):152636. (PMID: 31558304)
Oncotarget. 2017 Jul 12;8(46):81572-81582. (PMID: 29113415)
Cell Commun Signal. 2022 Jun 17;20(1):92. (PMID: 35715860)
Biochem J. 2001 Feb 1;353(Pt 3):417-39. (PMID: 11171037)
Int J Clin Oncol. 2020 Apr;25(4):570-583. (PMID: 31894433)
Cell Death Dis. 2018 Aug 28;9(9):854. (PMID: 30154401)
Cancer Res. 2011 Nov 15;71(22):7061-70. (PMID: 21975935)
Mol Cancer Ther. 2011 May;10(5):720-31. (PMID: 21393425)
PeerJ. 2022 Oct 25;10:e14263. (PMID: 36312753)
Biomedicines. 2022 Jun 10;10(6):. (PMID: 35740397)
Cell. 2016 Jun 30;166(1):21-45. (PMID: 27368099)
Ann Surg Oncol. 2011 Jun;18(6):1575-81. (PMID: 21431408)
Int J Clin Exp Med. 2014 Sep 15;7(9):2519-29. (PMID: 25356105)
J Clin Oncol. 2019 Aug 10;37(23):2028-2040. (PMID: 31084544)
J Gastrointest Oncol. 2021 Oct;12(5):2123-2131. (PMID: 34790379)
J Exp Clin Cancer Res. 2018 Sep 12;37(1):225. (PMID: 30208924)
Sci Signal. 2014 Sep 23;7(344):re8. (PMID: 25249658)
فهرسة مساهمة: Keywords: Gastric cancer; HIPEC; MiR-183-5p; Migration
المشرفين على المادة: 0 (MicroRNAs)
EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta)
0 (beta Catenin)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
0 (MIRN183 microRNA, human)
EC 3.1.3.16 (Protein Phosphatase 2)
0 (CTNNB1 protein, human)
EC 2.7.11.1 (GSK3B protein, human)
0 (Antineoplastic Agents, Phytogenic)
تواريخ الأحداث: Date Created: 20240909 Date Completed: 20240909 Latest Revision: 20240912
رمز التحديث: 20240912
مُعرف محوري في PubMed: PMC11383839
DOI: 10.1007/s00432-024-05923-y
PMID: 39249161
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-1335
DOI:10.1007/s00432-024-05923-y